ArticleContemporary oncology (Poznan, Poland)2020

Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study.

Lobna A Abdelaziz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.